Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
about
Intravenous immunoglobulin for Alzheimer's disease11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Lost in Translation (LiT): IUPHAR Review 6Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapyAmyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta poresRevolutionizing Alzheimer's disease and clinical trials through biomarkersInduced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapyNatural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the AgedCurrent Research Therapeutic Strategies for Alzheimer's Disease TreatmentRole of Hybrid Brain Imaging in Neuropsychiatric DisordersSuspected non-Alzheimer disease pathophysiology--concept and controversyInsights into Mechanisms of Chronic NeurodegenerationBlood-Based Proteomic Biomarkers of Alzheimer's Disease PathologyAnti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathyβ-Amyloid: the key peptide in the pathogenesis of Alzheimer's diseaseFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsGene expression parallels synaptic excitability and plasticity changes in Alzheimer's diseaseAnti-dementia medications: current prescriptions in clinical practice and new agents in progressPro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's DiseaseImpact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plansThe Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsGenetic heterogeneity in Alzheimer disease and implications for treatment strategiesInconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's diseasePredictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [CorrectedAlzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression.Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluationLongitudinal plasma amyloid beta in Alzheimer's disease clinical trials.Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease PhenotypesCrystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumabTargeting mRNA for Alzheimer's and related dementias.The antibody aducanumab reduces Aβ plaques in Alzheimer’s diseaseCheckpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous SystemHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesExcess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsSynaptopathies: synaptic dysfunction in neurological disorders - A review from students to studentsOral Delivery of Protein Drugs Bioencapsulated in Plant CellsSystems biology of neurodegenerative diseasesImmunotherapeutic approaches for Alzheimer's disease
P2860
Q24188215-4402B90A-FC13-414D-816F-B5920F200DEFQ24194742-19504EA0-8F22-4447-BDE8-47DA8C76FDE3Q24289150-ED0B8571-741A-49B9-947E-4AE3E6E6CA5EQ26382049-6790455E-D385-4E23-A2A5-26832CD8C58AQ26738355-DBF51972-7185-4E67-BEE3-A9B680633D1FQ26744882-1BA360E7-B6A1-4198-91B7-2ED48486D521Q26749360-06D6100A-2559-4959-9BD0-9841B45B8A1FQ26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2Q26765530-FC27B21C-E70E-4023-9F11-013FD7082478Q26768454-A40AC5AA-75D9-414C-ABD0-6BE3C6AC53A6Q26771270-B8C02249-6708-4E2F-9594-BBF9564C01AAQ26771732-762FAB0C-28E1-4A98-993B-C5100C8357AAQ26774743-0E983B4A-DFDE-44DF-B917-093A66B650F3Q26781451-73C481D6-F4B9-4F27-BA96-0FD66087DB11Q26781608-0F2446F0-EB86-4F62-80FE-F93ABB323923Q26784569-4D9BD11C-8A93-44FD-9D38-62EC0AEB716DQ26785375-D6BDAE57-E55D-4D21-BE66-5EBCC9A5AC8FQ26795400-B5AC6B1E-6731-44BD-8897-829BE33269E2Q26795492-9B97147C-658A-4EE1-87EA-9D83909D9ACAQ26801629-1D33A447-8927-485A-8997-AF4EA8440BE2Q26801647-0BCF14E7-2E86-4EFE-BF03-7DEEF6B38D34Q26801654-5DBE4C6D-B4D3-41DD-9E16-6FD47ED7D0CDQ26822002-BEB87D2B-F31A-4B39-83E8-E5DA74A82AF3Q26995802-5AEB4DBC-120E-4823-B052-C9F58A8869DFQ27003841-3BB7A830-4BDC-4EAF-B041-2794C18682B6Q27007436-BB5E7D69-B90E-47D8-A9F7-D785FA5D6593Q27301267-71FE2061-192A-4B9D-AAA8-A0570C41CDE8Q27303745-F25A0415-C3AA-4EEE-814F-66F3ED6E44B5Q27310276-E5F03421-A8E1-4BE5-A140-B9CC3558FA19Q27324311-A4C4AF03-3DBB-499F-A68E-22DD75A5B49BQ27684692-BBA296F5-B841-4D5E-B981-7B87FA0526BDQ27687153-6296C49D-EF46-440E-A082-299541EC9E2AQ28005463-16379FB4-B73F-4928-9EF3-294548BFA7E7Q28066906-F8E97C52-E668-44F1-98D8-0705762398AFQ28072061-8F1E44B4-C026-497A-9A96-9567BFB76385Q28075692-FB4628FF-41F9-4992-91C0-1642F0978602Q28077671-E01AB583-CAB2-467A-9A48-F8ABCAEE2B23Q28079063-9069B2DE-49BD-456E-8CB8-37F201F30252Q28080741-AFCC5147-59DA-4EBF-AB39-2D29C9CBBD35Q28081278-20FD2266-69F3-44A3-90A2-1473D098675A
P2860
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@ast
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@en
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@nl
type
label
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@ast
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@en
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@nl
prefLabel
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@ast
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@en
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@nl
P2093
P2860
P50
P356
P1476
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
@en
P2093
Anton P Porsteinsson
Bapineuzumab 301 and 302 Clinical Trial Investigators
Bijan Nejadnik
Daniel Wang
H Robert Brashear
Iulia Cristina Tudor
Julia Lull
Lawrence S Honig
P2860
P304
P356
10.1056/NEJMOA1304839
P407
P577
2014-01-01T00:00:00Z